1
|
Duan L, Shan W, Bo G, Lu G, Guo L. Qualitative (and Quantitative) Values of the Lung-RADS and Computed Tomography in Diagnosing Solitary Pulmonary Nodules. Diagnostics (Basel) 2022; 12:diagnostics12112699. [PMID: 36359542 PMCID: PMC9689942 DOI: 10.3390/diagnostics12112699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Revised: 10/30/2022] [Accepted: 10/31/2022] [Indexed: 11/09/2022] Open
Abstract
Background: Lung-RADS classification and CT signs can both help in the differential diagnosis of SPNs. The purpose of this study was to investigate the diagnostic value of these two methods and the combination of the two methods for solitary pulmonary nodules (SPNs). Methods: A total of 296 cases of SPNs were retrospectively analyzed. All the SPNs were classified according to the Lung-RADS grading version 1.1. The scores of each lesion were calculated according to their CT signs. Imaging features, such as the size and margin of the lesions, pleural traction, spiculation, lobulation, bronchial cutoff, air bronchogram, vacuoles, tumor vasculature, and cavity signs, were analyzed. The imaging results were compared with the pathology examination findings. Receiver operating characteristic (ROC) curves were applied to compare the values of the different methods in differentially diagnosing benign and malignant SPNs. Results: The sensitivity, specificity, and accuracy of Lung-RADS grading for diagnosing SPNs were 34.0%, 94.4%, and 47.6%, respectively. The area under the ROC curve (AUC) was 0.600 (p < 0.001). The sensitivity, specificity, and accuracy of the CT sign scores were 56.3%, 70.0%, and 60.5%, respectively, and the AUC was 0.657 (p < 0.001). The sensitivity, specificity, and accuracy of the combination of the two methods for diagnosing SPNs were 93.2%, 61.1%, and 83.5%, and the AUC was 0.777 (p < 0.001). Conclusion: The combination of Lung-RADS classification and CT signs significantly improved the differential diagnosis of SPNs.
Collapse
Affiliation(s)
- Lizhen Duan
- Department of Medical Imaging, The Affiliated Huai’an No.1 People’s Hospital of Nanjing Medical University, Huai’an 223300, China
| | - Wenli Shan
- Department of Medical Imaging, The Affiliated Huai’an No.1 People’s Hospital of Nanjing Medical University, Huai’an 223300, China
| | - Genji Bo
- Department of Medical Imaging, The Affiliated Huai’an No.1 People’s Hospital of Nanjing Medical University, Huai’an 223300, China
| | - Guangming Lu
- Department of Medical Imaging, The Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China
| | - Lili Guo
- Department of Medical Imaging, The Affiliated Huai’an No.1 People’s Hospital of Nanjing Medical University, Huai’an 223300, China
- Correspondence: ; Tel.: +86-13651549848
| |
Collapse
|
2
|
Ma H, Murphy C, Loscher CE, O’Kennedy R. Autoantibodies - enemies, and/or potential allies? Front Immunol 2022; 13:953726. [PMID: 36341384 PMCID: PMC9627499 DOI: 10.3389/fimmu.2022.953726] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Accepted: 08/24/2022] [Indexed: 08/13/2023] Open
Abstract
Autoantibodies are well known as potentially highly harmful antibodies which attack the host via binding to self-antigens, thus causing severe associated diseases and symptoms (e.g. autoimmune diseases). However, detection of autoantibodies to a range of disease-associated antigens has enabled their successful usage as important tools in disease diagnosis, prognosis and treatment. There are several advantages of using such autoantibodies. These include the capacity to measure their presence very early in disease development, their stability, which is often much better than their related antigen, and the capacity to use an array of such autoantibodies for enhanced diagnostics and to better predict prognosis. They may also possess capacity for utilization in therapy, in vivo. In this review both the positive and negative aspects of autoantibodies are critically assessed, including their role in autoimmune diseases, cancers and the global pandemic caused by COVID-19. Important issues related to their detection are also highlighted.
Collapse
Affiliation(s)
- Hui Ma
- School of Biotechnology, Dublin City University, Dublin, Ireland
| | - Caroline Murphy
- School of Biotechnology, Dublin City University, Dublin, Ireland
| | | | - Richard O’Kennedy
- School of Biotechnology, Dublin City University, Dublin, Ireland
- Research, Development and Innovation, Qatar Foundation, Doha, Qatar
- Hamad Bin Khalifa University, Doha, Qatar
| |
Collapse
|
3
|
Radhakrishnan D, Mohanan S, Choi G, Choy JH, Tiburcius S, Trinh HT, Bolan S, Verrills N, Tanwar P, Karakoti A, Vinu A. The emergence of nanoporous materials in lung cancer therapy. SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS 2022; 23:225-274. [PMID: 35875329 PMCID: PMC9307116 DOI: 10.1080/14686996.2022.2052181] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 01/31/2022] [Accepted: 03/08/2022] [Indexed: 06/15/2023]
Abstract
Lung cancer is one of the most common cancers, affecting more than 2.1 million people across the globe every year. A very high occurrence and mortality rate of lung cancer have prompted active research in this area with both conventional and novel forms of therapies including the use of nanomaterials based drug delivery agents. Specifically, the unique physico-chemical and biological properties of porous nanomaterials have gained significant momentum as drug delivery agents for delivering a combination of drugs or merging diagnosis with targeted therapy for cancer treatment. This review focuses on the emergence of nano-porous materials for drug delivery in lung cancer. The review analyses the currently used nanoporous materials, including inorganic, organic and hybrid porous materials for delivering drugs for various types of therapies, including chemo, radio and phototherapy. It also analyses the selected research on stimuli-responsive nanoporous materials for drug delivery in lung cancer before summarizing the various findings and projecting the future of emerging trends. This review provides a strong foundation for the current status of the research on nanoporous materials, their limitations and the potential for improving their design to overcome the unique challenges of delivering drugs for the treatment of lung cancer.
Collapse
Affiliation(s)
- Deepika Radhakrishnan
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Shan Mohanan
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Goeun Choi
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
- Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan31116, Republic of Korea
- College of Science and Technology, Dankook University, Cheonan31116, Republic of Korea
- Department of Nanobiomedical Science and BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan31116, Korea
| | - Jin-Ho Choy
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
- Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan31116, Republic of Korea
- Course, College of Medicine, Dankook UniversityDepartment of Pre-medical, Cheonan31116, Korea
- Tokyo Tech World Research Hub Initiative (WRHI), Institute of Innovative Research, Tokyo Institute of Technology, Yokohama226-8503, Japan
| | - Steffi Tiburcius
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Hoang Trung Trinh
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Shankar Bolan
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Nikki Verrills
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
- School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellness, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Pradeep Tanwar
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
- School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellness, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Ajay Karakoti
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| | - Ajayan Vinu
- Global Innovative Centre for Advanced Nanomaterials, College of Engineering, Science and Environment, School of Engineering, The University of Newcastle, Callaghan, NSW, 2308, Australia
| |
Collapse
|
4
|
Wang Z, Li H, Liu T, Sun Z, Yang F, Jiang G. Development and External Validation of a Nomogram for Predicting Cancer-Specific Survival of Non-Small Cell Lung Cancer Patients With Ipsilateral Pleural Dissemination. Front Oncol 2021; 11:645486. [PMID: 34350108 PMCID: PMC8327084 DOI: 10.3389/fonc.2021.645486] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Accepted: 06/28/2021] [Indexed: 12/25/2022] Open
Abstract
Background Non-small-cell lung cancer (NSCLC) patients with ipsilateral pleural dissemination are defined as M1a in the eighth of American Joint Committee on Cancer (AJCC) TNM staging. We aimed to build a nomogram to predict lung cancer specific survival (LCSS) of NSCLC patients with ipsilateral pleural dissemination and to compare the impact of primary tumor resection (PTR) on LCSS among patients with different features. Methods A total of 3,918 NSCLC patients with ipsilateral pleural dissemination were identified from the Surveillance, Epidemiology, and End Results (SEER) database. We selected and integrated significant prognostic factors based on competing risk regression to build a nomogram. The model was subjected to internal validation within SEER cohort and external validation with the cohort of 97 patients from Peking University People’s Hospital. Results Age (P < 0.001), gender (P = 0.037), T stage (P = 0.002), N stage (P < 0.001), metastasis pattern (P = 0.005), chemotherapy (P < 0.001), and PTR (P < 0.001) were independent prognostic factors. The calibration curves presented a good consistency and the Harrell’s C-index of nomogram were 0.682 (95%CI: 0.673–0.691), 0.687 (95%CI: 0.670–0.704) and 0.667 (95%CI: 0.584–0.750) in training, internal, and external validation cohort, respectively. Interaction tests suggested a greater LCSS difference caused by PTR in patients without chemotherapy (P < 0.001). Conclusions We developed a nomogram based on competing risk regression to reliably predict prognosis of NSCLC patients with ipsilateral pleural dissemination and validated this nomogram in an external Chinese cohort. This novel nomogram might be a practical tool for clinicians to anticipate the 1-, 3- and 5-year LCSS for NSCLC patients with pleural dissemination. Subgroup analysis indicated that patients without chemotherapy could get more benefit from PTR. In order to assess the role of PTR in the management of M1a patients more accurately, further prospective study would be urgently required.
Collapse
Affiliation(s)
- Zhenfan Wang
- Department of Thoracic Surgery, Centre of Thoracic Minimally Invasive Surgery, Peking University People's Hospital, Beijing, China
| | - Hao Li
- Department of Thoracic Surgery, Centre of Thoracic Minimally Invasive Surgery, Peking University People's Hospital, Beijing, China
| | - Taorui Liu
- Department of Thoracic Surgery, Centre of Thoracic Minimally Invasive Surgery, Peking University People's Hospital, Beijing, China
| | - Zewen Sun
- Department of Thoracic Surgery, Centre of Thoracic Minimally Invasive Surgery, Peking University People's Hospital, Beijing, China
| | - Fan Yang
- Department of Thoracic Surgery, Centre of Thoracic Minimally Invasive Surgery, Peking University People's Hospital, Beijing, China
| | - Guanchao Jiang
- Department of Thoracic Surgery, Centre of Thoracic Minimally Invasive Surgery, Peking University People's Hospital, Beijing, China
| |
Collapse
|
5
|
Zhang Y, Simoff MJ, Ost D, Wagner OJ, Lavin J, Nauman B, Hsieh MC, Wu XC, Pettiford B, Shi L. Understanding the patient journey to diagnosis of lung cancer. BMC Cancer 2021; 21:402. [PMID: 33853552 PMCID: PMC8045203 DOI: 10.1186/s12885-021-08067-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Accepted: 03/08/2021] [Indexed: 12/26/2022] Open
Abstract
Objective This research describes the clinical pathway and characteristics of two cohorts of patients. The first cohort consists of patients with a confirmed diagnosis of lung cancer while the second consists of patients with a solitary pulmonary nodule (SPN) and no evidence of lung cancer. Linked data from an electronic medical record and the Louisiana Tumor Registry were used in this investigation. Materials and methods REACHnet is one of 9 clinical research networks (CRNs) in PCORnet®, the National Patient-Centered Clinical Research Network and includes electronic health records for over 8 million patients from multiple partner health systems. Data from Ochsner Health System and Tulane Medical Center were linked to Louisiana Tumor Registry (LTR), a statewide population-based cancer registry, for analysis of patient’s clinical pathways between July 2013 and 2017. Patient characteristics and health services utilization rates by cancer stage were reported as frequency distributions. The Kaplan-Meier product limit method was used to estimate the time from index date to diagnosis by stage in lung cancer cohort. Results A total of 30,559 potentially eligible patients were identified and 2929 (9.58%) had primary lung cancer. Of these, 1496 (51.1%) were documented in LTR and their clinical pathway to diagnosis was further studied. Time to diagnosis varied significantly by cancer stage. A total of 24,140 patients with an SPN were identified in REACHnet and 15,978 (66.6%) had documented follow up care for 1 year. 1612 (10%) had no evidence of any work up for their SPN. The remaining 14,366 had some evidence of follow up, primarily office visits and additional chest imaging. Conclusion In both cohorts multiple biopsies were evident in the clinical pathway. Despite clinical workup, 70% of patients in the lung cancer cohort had stage III or IV disease. In the SPN cohort, only 66% were identified as receiving a diagnostic work-up. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-021-08067-1.
Collapse
Affiliation(s)
- Yichen Zhang
- Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal Street, Suite 1900, New Orleans, LA, 70112, USA
| | - Michael J Simoff
- Bronchoscopy and Interventional Pulmonology, Lung Cancer Screening Program, Pulmonary & Critical Care Medicine, Henry Ford Hospital, Wayne State University School of Medicine, 2799 West Grand Boulevard, Detroit, MI, 48202, USA.
| | - David Ost
- Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | | | - James Lavin
- Intuitive, 1020 Kifer Road, Sunnyvale, CA, 94086, USA
| | - Beth Nauman
- Louisiana Public Health Institute, 1515 Poydras Street #1200, New Orleans, LA, 70112, USA
| | - Mei-Chin Hsieh
- Louisiana State University Health Science Center, 433 Bolivar St, New Orleans, LA, 70112, USA
| | - Xiao-Cheng Wu
- Louisiana State University Health Science Center, 433 Bolivar St, New Orleans, LA, 70112, USA
| | - Brian Pettiford
- Ochsner Health System, 1514 Jefferson Highway, Jefferson, LA, 70121, USA
| | - Lizheng Shi
- Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal Street, Suite 1900, New Orleans, LA, 70112, USA
| |
Collapse
|
6
|
Nøst TH, Holden M, Dønnem T, Bøvelstad H, Rylander C, Lund E, Sandanger TM. Transcriptomic signals in blood prior to lung cancer focusing on time to diagnosis and metastasis. Sci Rep 2021; 11:7406. [PMID: 33795786 PMCID: PMC8017014 DOI: 10.1038/s41598-021-86879-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Accepted: 02/02/2021] [Indexed: 12/21/2022] Open
Abstract
Recent studies have indicated that there are functional genomic signals that can be detected in blood years before cancer diagnosis. This study aimed to assess gene expression in prospective blood samples from the Norwegian Women and Cancer cohort focusing on time to lung cancer diagnosis and metastatic cancer using a nested case–control design. We employed several approaches to statistically analyze the data and the methods indicated that the case–control differences were subtle but most distinguishable in metastatic case–control pairs in the period 0–3 years prior to diagnosis. The genes of interest along with estimated blood cell populations could indicate disruption of immunological processes in blood. The genes identified from approaches focusing on alterations with time to diagnosis were distinct from those focusing on the case–control differences. Our results support that explorative analyses of prospective blood samples could indicate circulating signals of disease-related processes.
Collapse
Affiliation(s)
- Therese H Nøst
- Department of Community Medicine, UiT - The Arctic University of Norway, Langnes, P.O. Box 6050, 9037, Tromsø, Norway.
| | | | - Tom Dønnem
- Department of Oncology, University Hospital of Northern Norway, Tromsø, Norway.,Department of Clinical Medicine, UiT - The Artic University of Norway, Tromsø, Norway
| | - Hege Bøvelstad
- Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway
| | - Charlotta Rylander
- Department of Community Medicine, UiT - The Arctic University of Norway, Langnes, P.O. Box 6050, 9037, Tromsø, Norway
| | - Eiliv Lund
- Department of Community Medicine, UiT - The Arctic University of Norway, Langnes, P.O. Box 6050, 9037, Tromsø, Norway.,Department of Research, Institute of Population-Based Cancer Research, Cancer Registry of Norway, Oslo, Norway
| | - Torkjel M Sandanger
- Department of Community Medicine, UiT - The Arctic University of Norway, Langnes, P.O. Box 6050, 9037, Tromsø, Norway
| |
Collapse
|
7
|
Chiu YW, Kao YH, Simoff MJ, Ost DE, Wagner O, Lavin J, Culbertson RA, Smith DG. Costs of Biopsy and Complications in Patients with Lung Cancer. CLINICOECONOMICS AND OUTCOMES RESEARCH 2021; 13:191-200. [PMID: 33762834 PMCID: PMC7982449 DOI: 10.2147/ceor.s295494] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 03/04/2021] [Indexed: 12/26/2022] Open
Abstract
Purpose To describe the distribution of diagnostic procedures, rates of complications, and total cost of biopsies for patients with lung cancer. Patients and Methods Observational study using data from IBM Marketscan® Databases for continuously insured adult patients with a primary lung cancer diagnosis and treatment between July 2013 and June 2017. Costs of lung cancer diagnosis covered 6 months prior to index biopsy through treatment. Costs of chest CT scans, biopsy, and post-procedural complications were estimated from total payments. Costs of biopsies incidental to inpatient admissions were estimated by comparable outpatient biopsies. Results The database included 22,870 patients who had a total of 37,160 biopsies, of which 16,009 (43.1%) were percutaneous, 14,997 (40.4%) bronchoscopic, 4072 (11.0%) surgical and 2082 (5.6%) mediastinoscopic. Multiple biopsies were performed on 41.9% of patients. The most common complications among patients receiving only one type of biopsy were pneumothorax (1304 patients, 8.4%), bleeding (744 patients, 4.8%) and intubation (400 patients, 2.6%). However, most complications did not require interventions that would add to costs. Median total costs were highest for inpatient surgical biopsies ($29,988) and lowest for outpatient percutaneous biopsies ($1028). Repeat biopsies of the same type increased costs by 40–80%. Complications account for 13% of total costs. Conclusion Costs of biopsies to confirm lung cancer diagnosis vary substantially by type of biopsy and setting. Multiple biopsies, inpatient procedures and complications result in higher costs.
Collapse
Affiliation(s)
- Yu-Wen Chiu
- Health Policy & Systems Management, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
| | - Yu-Hsiang Kao
- Health Policy & Systems Management, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
| | - Michael J Simoff
- Pulmonary and Critical Care Medicine, Henry Ford Hospital, Detroit, Michigan, USA
| | - David E Ost
- Department of Pulmonology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | | | - James Lavin
- Intuitive Surgical, Sunnyvale, California, USA
| | - Richard A Culbertson
- Health Policy & Systems Management, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
| | - Dean G Smith
- Health Policy & Systems Management, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
| |
Collapse
|
8
|
Srivastava A, Amreddy N, Pareek V, Chinnappan M, Ahmed R, Mehta M, Razaq M, Munshi A, Ramesh R. Progress in extracellular vesicle biology and their application in cancer medicine. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2020; 12:e1621. [PMID: 32131140 PMCID: PMC7317410 DOI: 10.1002/wnan.1621] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 01/15/2020] [Accepted: 01/29/2020] [Indexed: 12/11/2022]
Abstract
Under the broader category of extracellular vesicles (EVs), exosomes are now well recognized for their contribution and potential for biomedical research. During the last ten years, numerous technologies for purification and characterization of EVs have been developed. This enhanced knowledge has resulted in the development of novel applications of EVs. This review is an attempt to capture the exponential growth observed in EV science in the last decade and discuss the future potential to improve our understanding of EVs, develop technologies to overcome current limitations, and advance their utility for human benefit, especially in cancer medicine. This article is categorized under:Therapeutic Approaches and Drug Discovery > Emerging Technologies Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Collapse
Affiliation(s)
- Akhil Srivastava
- Department of Pathology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | - Narsireddy Amreddy
- Department of Pathology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | - Vipul Pareek
- Department of Hematology and Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | - Mahendran Chinnappan
- Department of Pathology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | - Rebaz Ahmed
- Department of Pathology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | - Meghna Mehta
- Department of Radiation Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | - Mohammad Razaq
- Department of Hematology and Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | - Anupama Munshi
- Department of Radiation Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | - Rajagopal Ramesh
- Department of Pathology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| |
Collapse
|
9
|
Ensuring the Safety and Security of Frozen Lung Cancer Tissue Collections through the Encapsulation of Dried DNA. Cancers (Basel) 2018; 10:cancers10060195. [PMID: 29891792 PMCID: PMC6025404 DOI: 10.3390/cancers10060195] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 06/08/2018] [Accepted: 06/08/2018] [Indexed: 02/06/2023] Open
Abstract
Collected specimens for research purposes may or may not be made available depending on their scarcity and/or on the project needs. Their protection against degradation or in the event of an incident is pivotal. Duplication and storage on a different site is the best way to assure their sustainability. The conservation of samples at room temperature (RT) by duplication can facilitate their protection. We describe a security system for the collection of non-small cell lung cancers (NSCLC) stored in the biobank of the Nice Hospital Center, France, by duplication and conservation of lyophilized (dried), encapsulated DNA kept at RT. Therefore, three frozen tissue collections from non-smoking, early stage and sarcomatoid carcinoma NSCLC patients were selected for this study. DNA was extracted, lyophilized and encapsulated at RT under anoxic conditions using the DNAshell technology. In total, 1974 samples from 987 patients were encapsulated. Six and two capsules from each sample were stored in the biobanks of the Nice and Grenoble (France) Hospitals, respectively. In conclusion, DNA maintained at RT allows for the conservation, duplication and durability of collections of interest stored in biobanks. This is a low-cost and safe technology that requires a limited amount of space and has a low environmental impact.
Collapse
|
10
|
Qin Y, Zhou X, Huang C, Li L, Liu H, Liang N, Chen Y, Ma D, Han Z, Xu X, He J, Li S. Serum miR-342-3p is a novel diagnostic and prognostic biomarker for non-small cell lung cancer. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2018; 11:2742-2748. [PMID: 31938391 PMCID: PMC6958259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Accepted: 03/28/2018] [Indexed: 06/10/2023]
Abstract
Lung cancer is the leading cause of cancer-related mortality and non-small cell lung carcinoma (NSCLC) is the most common type. MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level. Aberrant expression of miRNAs has been demonstrated to be a prominent feature in NSCLC. The aim of this study was to determine the potential clinical value of serum miR-342-3p in NSCLC. We first evaluated the miR-342-3p levels in NSCLC cell lines, culture media of NSCLC cell lines, and serum samples from NSCLC patients as well as in their respective controls. The associations between serum miR-342-3p levels and clinicopathological parameters as well as clinical outcome were then determined. miR-342-3p expression was significantly downregulated in NSCLC cell lines, culture media of NSCLC cell lines, and the serum samples from NSCLC patients compared to their controls. Serum miR-342-3p discriminated NSCLC patients from healthy individuals. Low expression of serum miR-342-3p was significantly associated with advanced TNM stage and positive lymph node metastasis. In addition, NSCLC patients in the low serum miR-342-3p expression group had remarkably shorter overall survival than those in the high serum miR-342-3p expression group. Serum miR-342-3p was shown to be an independent prognosis factor. In conclusion, serum miR-342-3p might be a promising biomarker for NSCLC that can be used to improve diagnosis and prognosis.
Collapse
Affiliation(s)
- Yingzhi Qin
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| | - Xiaoyun Zhou
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| | - Cheng Huang
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| | - Li Li
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| | - Hongsheng Liu
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| | - Naixin Liang
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| | - Yeye Chen
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| | - Dongjie Ma
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| | - Zhijun Han
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| | - Xiaohui Xu
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| | - Jia He
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| | - Shanqing Li
- Department of Thoracic Surgery, Peking Union Medical College Hospital (PUMCH)Beijing 100730, China
- Peking Union Medical College, Chinese Academy of Medical SciencesBeijing 100730, China
| |
Collapse
|
11
|
Han Z, Wang T, Han S, Chen Y, Chen T, Jia Q, Li B, Li B, Wang J, Chen G, Liu G, Gong H, Wei H, Zhou W, Liu T, Xiao J. Low-expression of TMEM100 is associated with poor prognosis in non-small-cell lung cancer. Am J Transl Res 2017; 9:2567-2578. [PMID: 28560005 PMCID: PMC5446537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Accepted: 02/09/2017] [Indexed: 06/07/2023]
Abstract
Transmembrane protein 100 (TMEM100) was first identified as a transcript from the mouse genome. Recent studies have demonstrated that TMEM100 is involved in hepatocellular carcinoma (HCC) malignancy. However, the distribution and clinical significance of TMEM100 in non-small-cell lung carcinoma (NSCLC) remains poorly understood. This study aims to explore the significance of TMEM100 expression in NSCLC. We found that TMEM100 expression was significantly reduced in NSCLC tissues when compared with that in adjacent normal lung tissues (P<0.001). Kaplan-Meier survival analysis showed that overall survival of patients with lower expressions of TMEM100 was significantly shorter (n=152, P<0.05). In addition, TMEM100 overexpression in NSCLC cell lines inhibited cell proliferation in vitro and in vivo. Transwell migration and invasion assay showed that TMEM100 significantly suppressed the migration and invasion of NSCLC cell lines. In contrast, knocking down TMEM100 promoted NSCLC proliferation and migration. Finally, we found that TMEM100 worked as a cancer suppressor gene mainly by inhibiting the TNF signaling pathway. In conclusion, TMEM100 acted as a tumor suppressor in NSCLC and may prove to be a potential prognostic biomarker and therapeutic target for NSCLC.
Collapse
Affiliation(s)
- Zhitao Han
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
- Department of Spine Surgery, Ruikang Hospital, Guangxi University of Traditional Chinese MedicineNanning, China
| | - Ting Wang
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
| | - Shuai Han
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
| | - Yuanming Chen
- Department of Spine Surgery, Ruikang Hospital, Guangxi University of Traditional Chinese MedicineNanning, China
| | - Tianrui Chen
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
| | - Qi Jia
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
| | - Bo Li
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
| | - Binbin Li
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
| | - Jing Wang
- Department of Anatomy, Xuzhou Medical CollegeXuzhou, China
| | | | - Ge Liu
- Taishan Medical UniversityTai’an, China
| | - Haiyi Gong
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
| | - Haifeng Wei
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
| | - Wang Zhou
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
| | - Tielong Liu
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
| | - Jianru Xiao
- Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical UniversityShanghai, China
| |
Collapse
|
12
|
Biaoxue R, Hua L, Wenlong G, Shuanying Y. Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies. BMC Cancer 2016; 16:836. [PMID: 27809798 PMCID: PMC5093952 DOI: 10.1186/s12885-016-2882-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Accepted: 10/24/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Previous studies have disclosed that serum amyloid A (SAA) is likely involved in the lung cancer pathogenesis and progression. We performed a systematic evaluation and meta-analysis to disclose the correlation between the expression of SAA and lung cancer and to evaluate its value for lung cancer diagnosis. METHODS We searched the relevant articles from the databases of Medline, Embase, Cochrance Library and Web of Science and calculated the standardized mean difference (SMD) with 95 % confidence interval (CI) to assess the expression difference of SAA between lung cancer and normal patients. Moreover, we counted the positive rate, sensitivity and specificity and drew a summary receiver operating characteristic curve (SROC) to evaluate the diagnostic value of SAA for lung cancer. RESULTS A total of nine studies with 1392 individuals were included in this analysis. The results showed an increased SAA was correlated with the incidence of lung cancer (P < 0.001), especially with the lung squamous cell carcinoma (LSCC) (p = 0.012). The overall sensitivity and specificity of SAA for discerning lung cancer was 0.59 (95 % CI: 0.54-0.63) and 0.92 (95 % CI: 0.88-0.95), respectively. The area under the SROC curve was 0.9066 (SE = 0.0437). CONCLUSIONS Increased SAA in lung cancer was intimately correlated with the development and progression of lung cancer. A higher specificity of SAA suggested that it should be a significant biomarker for discerning lung cancer from normal individuals, especially for LSCC (p = 0.012).
Collapse
Affiliation(s)
- Rong Biaoxue
- Department of Respiratory Medicine, First Affiliated Hospital, Xi’an Medical University, 48 Fenghao West Road, Xi’an, 710077 China
- Research Center of Prevention and Treatment of Respiratory Disease, Xi’an, Shaanxi Province 710077 China
| | - Liu Hua
- Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, China
| | - Gao Wenlong
- Department of Statistics and Epidemiology, Medical College, Lanzhou University, Lanzhou, China
| | - Yang Shuanying
- Department of Respiratory Medicine, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China
| |
Collapse
|
13
|
Sun S, Wang Z, Tang F, Hu P, Yang Z, Xue C, Gong J, Shi L, Xie C. ATG7 promotes the tumorigenesis of lung cancer but might be dispensable for prognosis predication: a clinicopathologic study. Onco Targets Ther 2016; 9:4975-81. [PMID: 27563251 PMCID: PMC4986672 DOI: 10.2147/ott.s107876] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Lung cancer is the most frequent cause of cancer-related death worldwide. Dysregulated autophagy is often observed in lung cancer. Autophagy-related 7 (ATG7) is an autophagy gene that is essential for the biogenesis of autophagosomes. Although ATG7-deficient mouse models have demonstrated that ATG7-dependent autophagy is required for lung cancer tumorigenesis, the relationship between ATG7 expression levels and human lung cancer is unclear. Here, we demonstrate that ATG7 was overexpressed in human lung cancer tissues compared with normal tissues. However, ATG7 expression was not associated with tumor differentiation, tumor size, or TNM stage. Moreover, the overexpression of ATG7 did not influence the overall survival of the lung cancer patients. Therefore, our results indicate that ATG7 might be dispensable for tumor growth and chemotherapy efficacy in human lung cancer.
Collapse
Affiliation(s)
- Shaoxing Sun
- Department of Radiation and Medical Oncology; Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University
| | - Zhihao Wang
- Department of Radiation and Medical Oncology; Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University
| | - Fang Tang
- Department of Radiation and Medical Oncology; Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University
| | - Pengchao Hu
- Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Wuhan University
| | - Zetian Yang
- Department of Thoracic and Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China
| | - Chao Xue
- Department of Thoracic and Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China
| | - Jun Gong
- Department of Radiation and Medical Oncology; Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University
| | - Liu Shi
- Department of Radiation and Medical Oncology; Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University
| | - Conghua Xie
- Department of Radiation and Medical Oncology; Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University
| |
Collapse
|
14
|
Sánchez-Ares M, Cameselle-Teijeiro JM, Vázquez-Estévez S, Lázaro-Quintela M, Vázquez-Boquete Á, Afonso-Afonso FJ, Casal-Rubio J, González-Piñeiro AL, Rico-Rodríguez Y, Fírvida-Pérez JL, Ruíz-Bañobre J, Couso E, Santomé L, Pérez-Becerra R, García-Campelo R, Amenedo M, Azpitarte-Raposeiras C, Antúnez J, Abdulkader I. Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia). Oncol Lett 2016; 12:1403-1407. [PMID: 27446444 PMCID: PMC4950728 DOI: 10.3892/ol.2016.4788] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2016] [Accepted: 05/10/2016] [Indexed: 12/17/2022] Open
Abstract
Identification of anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements is a standard diagnostic test in patients with advanced non-small cell lung cancer (NSCLC). The current study describes the experience of ALK rearrangement detection of a referral center in the public health care system of Galicia in North-Western Spain. The fluorescence in situ hybridization (FISH) patterns of the ALK gene and the clinical and pathological features of these patients are reported. This study is also of interest for comparative purposes due to the relative geographical isolation of the area, which could have contributed to particular genetic features. A total of 2,045 tissue samples from NSCLC patients were collected between October 2010 and July 2015 and tested for ALK rearrangements by FISH. Examination of 1,686 paraffin-embedded tissue specimens and 395 cytological samples (306 cell block preparations and 53 cytological smears) was conducted, and any associations between the FISH results and clinicopathological features were assessed. The rate of successful evaluation was marginally higher in tissue samples than in cytological samples (92.9% vs. 84.1%); this difference was not significant. ALK rearrangements were identified in 82 patients(4%): 65 (79.3%) in tissue specimens, 15 (18.3%) in cell block samples and 2 (2.4%) in cytological smears. This genetic translocation appeared to be associated with a non-smoking history, younger age, female gender, stage IV and adenocarcinoma histological type. The findings demonstrate that ALK evaluation by FISH is feasible in tissue and cytological samples. The clinical and pathological features of the ALK-positive series of patients are similar to those previously reported in the literature.
Collapse
Affiliation(s)
- María Sánchez-Ares
- Department of Anatomic Pathology, Clinical University Hospital, Galician Healthcare Service (SERGAS), 15706 Santiago de Compostela, Spain
| | - José M Cameselle-Teijeiro
- Department of Anatomic Pathology, Clinical University Hospital, Galician Healthcare Service (SERGAS), 15706 Santiago de Compostela, Spain; Department of Anatomic Pathology, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Sergio Vázquez-Estévez
- Department of Medical Oncology, Lucus Augusti University Hospital, SERGAS, 27003 Lugo, Spain
| | | | - Ángel Vázquez-Boquete
- Department of Anatomic Pathology, Clinical University Hospital, Galician Healthcare Service (SERGAS), 15706 Santiago de Compostela, Spain
| | - Francisco J Afonso-Afonso
- Department of Medical Oncology, University Hospital Complex Arquitecto Marcide-Novoa Santos, SERGAS, 15405 Ferrol, Spain
| | - Joaquín Casal-Rubio
- Department of Medical Oncology, University Hospital Complex, SERGAS, 36312 Vigo, Spain
| | - Ana L González-Piñeiro
- Department of Anatomic Pathology, University Hospital Complex, SERGAS, 36312 Vigo, Spain
| | - Yolanda Rico-Rodríguez
- Department of Anatomic Pathology, Clinical University Hospital, Galician Healthcare Service (SERGAS), 15706 Santiago de Compostela, Spain
| | - José L Fírvida-Pérez
- Department of Medical Oncology, Clinical University Hospital, SERGAS, 32005 Ourense, Spain
| | - Juan Ruíz-Bañobre
- Department of Medical Oncology, Clinical University Hospital, SERGAS, 15706 Santiago de Compostela, Spain
| | - Elena Couso
- Department of Anatomic Pathology, Clinical University Hospital, Galician Healthcare Service (SERGAS), 15706 Santiago de Compostela, Spain
| | - Lucía Santomé
- Department of Medical Oncology, Povisa Hospital, 36211 Vigo, Spain
| | - Raquel Pérez-Becerra
- Department of Anatomic Pathology, Clinical University Hospital, Galician Healthcare Service (SERGAS), 15706 Santiago de Compostela, Spain
| | - Rosario García-Campelo
- Department of Medical Oncology, Clinical University Hospital, SERGAS, 15006 A Coruña, Spain
| | - Margarita Amenedo
- Department of Medical Oncology, Centro Oncológico de Galicia, 15009 A Coruña, Spain
| | | | - José Antúnez
- Department of Anatomic Pathology, Clinical University Hospital, Galician Healthcare Service (SERGAS), 15706 Santiago de Compostela, Spain; Department of Anatomic Pathology, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Ihab Abdulkader
- Department of Anatomic Pathology, Clinical University Hospital, Galician Healthcare Service (SERGAS), 15706 Santiago de Compostela, Spain
| |
Collapse
|
15
|
Luo W, Lin Y, Meng S, Guo Y, Zhang J, Zhang W. miRNA-296-3p modulates chemosensitivity of lung cancer cells by targeting CX3CR1. Am J Transl Res 2016; 8:1848-1856. [PMID: 27186308 PMCID: PMC4859913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2015] [Accepted: 03/09/2016] [Indexed: 06/05/2023]
Abstract
Lung cancer is the most common type of cancer-related death in developed countries. MicroRNAs (miRNAs) are small non-coding RNAs, which regulates gene expression in cancer. Recent studies demonstrate that the microRNA-293-3p (miR-293-3p) may play as an oncogene or a tumor suppressor. However, its expression and roles in non-small cell lung cancer (NSCLC) is not known. In this study, our purpose is to investigate the expression and roles of miR-296-3p in NSCLC. The findings indicated that miR296-3p inhibited NSCLC cell proliferation, enhance the drug resistance, and apoptosis. Data of luciferase reporter assays demonstrated that the CX3CR1 gene was a direct regulator of tumorsuppressive miR296-3p. Moreover, overexpressed CX3CR1 was confirmed in NSCLC clinical specimens. Inhibition of CX3CR1 could inhibit cancer cellular survival and increase chemotherapy sensitivity. There was a negative relationship between miR296-3p and CX3CR1 expression in NSCLC tissues. Our study elucidates that miR296-3p plays a suppressive role in NSCLC by inhibiting CX3CR1 expression.
Collapse
Affiliation(s)
- Wen Luo
- Department of Respiratory, First Affiliated Hospital of Harbin Medical UniversityHarbin, China
| | - Yuanlong Lin
- Department of Infection, Fourth Affiliated Hospital of Harbin Medical UniversityHarbin, China
| | - Shanshan Meng
- Department of Respiratory, First Affiliated Hospital of Harbin Medical UniversityHarbin, China
| | - Yuening Guo
- Department of Respiratory, First Affiliated Hospital of Harbin Medical UniversityHarbin, China
| | - Jiawen Zhang
- Department of Respiratory, First Affiliated Hospital of Harbin Medical UniversityHarbin, China
| | - Wei Zhang
- Department of Respiratory, First Affiliated Hospital of Harbin Medical UniversityHarbin, China
| |
Collapse
|